Comparative Pharmacology
Head-to-head clinical analysis: ENSKYCE versus LEVLITE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENSKYCE versus LEVLITE.
ENSKYCE vs LEVLITE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ENSKYCE (fospropofol disodium) is a prodrug of propofol. It is hydrolyzed by alkaline phosphatases to release propofol, which acts as a positive allosteric modulator of GABA-A receptors, enhancing chloride conductance and producing sedation and anesthesia.
Levonorgestrel is a progestin that suppresses ovulation by inhibiting gonadotropin release (LH and FSH) and alters cervical mucus, endometrial thickness, and tubal motility.
2 g IV every 8 hours over 5 hours on days 1-3 of each 21-day cycle
One tablet (levonorgestrel 0.1 mg, ethinyl estradiol 0.02 mg) orally once daily for 21 days, followed by 7 placebo tablets.
None Documented
None Documented
12 hours (terminal); allows once-daily dosing in most patients
Terminal elimination half-life: 21-28 hours; clinical context: permits once-daily dosing
Renal: ~70% unchanged; Biliary/Fecal: ~20% as metabolites
Renal: ~50% (30% as unchanged drug, 20% as metabolites); Fecal: ~40%; Biliary: minor
Category C
Category C
Oral Contraceptive
Oral Contraceptive